# GLP-1 Receptor Agonist Safety: Pancreatitis Risk in Type 1 Diabetes > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/glp-1-receptor-agonist-safety-pancreatitis-risk-in-type-1-diabetes/ > **Published:** 2026-05-13T02:46:03-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T09:55:46-04:00 > **Clinical Summary:** GLP-1 pancreatitis risk was not increased in type 1 diabetes patients, according to safety data reviewed at a major medical conference. --- GLP-1 Clinical Relevance  #41Contextual Information  Background context; limited direct clinical applicability. ⚕ GLP-1 News  |  CED Clinic CommentaryObservational StudyType 1 DiabetesGLP-1 Receptor AgonistEndocrinologyAdults with Type 1 DiabetesDiabetic Ketoacidosis RiskAppetite RegulationPancreatitis SafetyOff-Label GLP-1 UseInsulin-Dependent Diabetes ManagementAdverse Event Monitoring Why This Matters Family medicine clinicians managing patients with type 1 diabetes on GLP-1 therapy have historically relied on limited evidence regarding safety in this population, making this data clinically relevant for broadening GLP-1 utilization beyond type 2 diabetes. The absence of increased DKA and pancreatitis risk in type 1 diabetes patients on GLP-1s addresses two major safety concerns that have constrained prescribing patterns in primary care. These findings enable more informed shared decision-making when considering GLP-1s for [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) or glycemic control in type 1 diabetes patients where dual benefits might be clinically indicated. Clinical Summary A recent analysis examined the safety profile of GLP-1 receptor agonists in adults with type 1 diabetes, specifically evaluating the risk of diabetic ketoacidosis and pancreatitis. The study investigated whether these agents, increasingly used off-label in type 1 diabetes despite regulatory approval limited to type 2 diabetes and obesity, increase the incidence of these serious complications. Data were systematically reviewed to determine event rates among users of GLP-1 receptor agonists compared to relevant control groups or baseline incidence rates in the type 1 diabetes population. The analysis found that GLP-1 receptor agonists did not elevate the risk for either diabetic ketoacidosis or pancreatitis among adults with type 1 diabetes. This finding is clinically significant because previous theoretical concerns about GLP-1 use in type 1 diabetes centered on the potential for euglycemic ketoacidosis, a condition where ketosis develops despite near-normal glucose levels, and on pancreatitis risk, which remains a recognized adverse effect class consideration across all GLP-1 agents. The results suggest that these specific safety concerns may not represent true clinical hazards when GLP-1 receptor agonists are used in the type 1 diabetes population. For prescribers considering GLP-1 receptor agonists in adults with type 1 diabetes where clinical circumstances warrant their use, these data provide reassurance regarding two major safety endpoints that have limited enthusiasm for off-label use in this population. However, this analysis addresses only diabetic ketoacidosis and pancreatitis risk and does not evaluate other relevant safety considerations or efficacy endpoints that should inform [clinical decision-making](https://cedclinic.com/cannabinoids-mental-health-systematic-review-evidence-insights/) in type 1 diabetes management. Clinical Takeaway Clinical Takeaway: Recent evidence suggests that GLP-1 receptor agonists do not increase the risk of diabetic ketoacidosis or acute pancreatitis in adults with type 1 diabetes, addressing a key safety concern that previously limited their use in this population. This finding expands the therapeutic options available for type 1 diabetes patients who need additional glycemic control or [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) beyond insulin alone. For family medicine practices, this means GLP-1 therapy can be considered as an adjunctive treatment in carefully selected type 1 diabetes patients, though insulin remains the foundation of their regimen. When discussing GLP-1 use with type 1 patients, clarify that while these agents appear safe regarding DKA and pancreatitis risks, baseline pancreatic function assessment and clear sick-day management protocols remain standard practice. Dr. Caplan’s Take “The emerging data on GLP-1 safety in type 1 diabetes is reassuring, and this particular finding on pancreatitis risk is important because it challenges some of the earlier theoretical concerns we had about these agents. What we’re learning is that GLP-1s can be carefully integrated into type 1 diabetes management when there’s appropriate clinical judgment and patient selection, which frankly opens up treatment options for patients who struggle with weight gain or metabolic complications despite optimal insulin therapy. From a [patient communication](https://cedclinic.com/shifting-public-attitudes-toward-cannabis/) standpoint, I’m now able to tell my type 1 diabetic patients that if they’re candidates for GLP-1 therapy, they shouldn’t avoid these drugs based solely on pancreatitis fears, though we still need to maintain vigilance around DKA prevention through proper sick day management and [patient education](https://cedclinic.com/medical-cannabis-patient-education-basics/). The key is that safety requires expertise in titration and monitoring, not blanket prohibition.” Clinical Perspective This emerging evidence suggesting GLP-1 receptor agonists do not significantly elevate DKA or pancreatitis risk in type 1 diabetes is clinically meaningful, as it addresses a primary safety concern that has historically limited off-label GLP-1 use in this population despite demonstrated glycemic and cardiovascular benefits. The data supports a more nuanced risk-benefit discussion with appropriate type 1 diabetic patients, particularly those with concurrent obesity or cardiovascular disease. Concrete action: Consider adding structured GLP-1 counseling protocols to your type 1 diabetes management toolkit, including baseline pancreatic assessment and [patient education](https://cedclinic.com/medical-cannabis-patient-education-basics/) on sick day management, while maintaining appropriate monitoring for the rare but serious DKA presentations that can still occur in this population. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20GLP-1s%20may%20not%20raise%20DKA%2C%20%3Cb%3Epancreatitis%3C%2Fb%3E%20risk%20in%20type%201%20diabetes%20-%20Healio%20%40drcaplan&url=https%3A%2F%2Fwww.healio.com%2Fnews%2Fendocrinology%2F20260505%2Fglp1s-may-not-raise-diabetic-ketoacidosis-pancreatitis-risk-in-type-1-diabetes)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.healio.com%2Fnews%2Fendocrinology%2F20260505%2Fglp1s-may-not-raise-diabetic-ketoacidosis-pancreatitis-risk-in-type-1-diabetes)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20GLP-1s%20may%20not%20raise%20DKA%2C%20%3Cb%3Epancreatitis%3C%2Fb%3E%20risk%20in%20type%201%20diabetes%20-%20Healio%20--%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fwww.healio.com%2Fnews%2Fendocrinology%2F20260505%2Fglp1s-may-not-raise-diabetic-ketoacidosis-pancreatitis-risk-in-type-1-diabetes)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [Read full article at Healio](https://www.healio.com/news/endocrinology/20260505/glp1s-may-not-raise-diabetic-ketoacidosis-pancreatitis-risk-in-type-1-diabetes) Nationwide GLP-1 Care Looking for thoughtful, physician-led GLP-1 guidance? CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care. [Learn More](https://cedclinic.com/metabolic/) [Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services) Table of Contents - [FAQ](#FAQ)[Are GLP-1 drugs safe to use if I have type 1 diabetes?](#Are_GLP-1_drugs_safe_to_use_if_I_have_type_1_diabetes) - [Can GLP-1 medications cause diabetic ketoacidosis in type 1 diabetes patients?](#Can_GLP-1_medications_cause_diabetic_ketoacidosis_in_type_1_diabetes_patients) - [Will GLP-1 therapy increase my risk of pancreatitis?](#Will_GLP-1_therapy_increase_my_risk_of_pancreatitis) - [Why were doctors concerned about GLP-1s and type 1 diabetes safety?](#Why_were_doctors_concerned_about_GLP-1s_and_type_1_diabetes_safety) - [Can I use GLP-1 drugs if I’m insulin dependent?](#Can_I_use_GLP-1_drugs_if_I8217m_insulin_dependent) - [What should I monitor if I take a GLP-1 medication with type 1 diabetes?](#What_should_I_monitor_if_I_take_a_GLP-1_medication_with_type_1_diabetes) - [Are there any type 1 diabetes patients who should not use GLP-1s?](#Are_there_any_type_1_diabetes_patients_who_should_not_use_GLP-1s) - [How does GLP-1 therapy work differently in type 1 versus type 2 diabetes?](#How_does_GLP-1_therapy_work_differently_in_type_1_versus_type_2_diabetes) - [Do I need to stop taking insulin if I start GLP-1 therapy?](#Do_I_need_to_stop_taking_insulin_if_I_start_GLP-1_therapy) - [What does this new safety data mean for my diabetes management?](#What_does_this_new_safety_data_mean_for_my_diabetes_management) - [Related](#Related) ## FAQ #### Are GLP-1 drugs safe to use if I have type 1 diabetes? Recent research suggests that GLP-1 receptor agonists may be safe for adults with type 1 diabetes, showing no increased risk for serious complications like diabetic ketoacidosis or pancreatitis. However, you should only use these medications under close supervision from your doctor who specializes in diabetes care. #### Can GLP-1 medications cause diabetic ketoacidosis in type 1 diabetes patients? Current evidence indicates that GLP-1 receptor agonists do not appear to increase the risk of diabetic ketoacidosis in people with type 1 diabetes. This addresses a previous safety concern that doctors had about using these medications in this population. #### Will GLP-1 therapy increase my risk of pancreatitis? Studies now suggest that GLP-1 receptor agonists do not raise the risk of pancreatitis in adults with type 1 diabetes. This is reassuring news for patients considering these medications as part of their treatment plan. #### Why were doctors concerned about GLP-1s and type 1 diabetes safety? Early concerns focused on whether GLP-1 medications might trigger dangerous complications like diabetic ketoacidosis or pancreatic inflammation in type 1 diabetes patients. Newer research is helping clarify that these risks may not be as significant as initially thought. #### Can I use GLP-1 drugs if I’m insulin dependent? Many people with type 1 diabetes require insulin, and recent evidence suggests GLP-1 receptor agonists can potentially be used alongside insulin therapy. You and your doctor should discuss whether this combination makes sense for your specific situation. #### What should I monitor if I take a GLP-1 medication with type 1 diabetes? While pancreatitis and ketoacidosis risks appear lower than previously feared, your doctor will want you to monitor blood sugar levels closely and report any signs of abdominal pain, persistent nausea, or unusual thirst. Regular follow-up appointments are essential when using any new diabetes medication. #### Are there any type 1 diabetes patients who should not use GLP-1s? Certain conditions or circumstances may make GLP-1 medications inappropriate for some individuals, including those with a personal or [family history](https://cedclinic.com/genetic-nurture-substance-use-intergenerational-risk/) of medullary thyroid cancer or multiple endocrine neoplasia. Your doctor will evaluate your full medical history to determine if these drugs are right for you. #### How does GLP-1 therapy work differently in type 1 versus type 2 diabetes? GLP-1 medications work by increasing insulin release and slowing digestion in both types of diabetes, but type 1 patients typically need to adjust their insulin doses when starting these drugs. The safety profile appears more favorable than doctors initially anticipated. #### Do I need to stop taking insulin if I start GLP-1 therapy? Most people with type 1 diabetes will continue needing insulin even when taking GLP-1 medications, though your insulin doses may need to be reduced. Never stop or change your insulin regimen without explicit instructions from your doctor. #### What does this new safety data mean for my diabetes management? This research expands the potential treatment options available for type 1 diabetes by suggesting GLP-1 receptor agonists can be used more safely than previously thought. Talk with your diabetes specialist about whether adding a GLP-1 medication might help improve your blood sugar control and overall health. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).